Is J B Chemicals & overvalued or undervalued?

As of November 27, 2020, J B Chemicals & is considered very expensive and overvalued with a PE Ratio of 40.03 and an EV to EBITDA of 25.18, significantly higher than peers like Sun Pharma and Cipla, despite a recent return of 10.28% that underperformed the Sensex's 3.84%.

As of 27 November 2020, the valuation grade for J B Chemicals & has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE Ratio of 40.03, an EV to EBITDA of 25.18, and a PEG Ratio of 2.12, all of which are notably high compared to its peers.<BR><BR>In comparison, Sun Pharma has a PE Ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla, which is rated as attractive, has a PE Ratio of 22.99 and an EV to EBITDA of 15.93. These comparisons highlight that J B Chemicals & is trading at a premium relative to its peers. Additionally, while the stock has seen a return of 10.28% over the past month, it has underperformed the Sensex, which returned 3.84% in the same period, reinforcing the notion of overvaluation.

When is the next results date for J B Chemicals &?

No Upcoming Board Meetings

Who are in the management team of J B Chemicals &?

As of March 2023, the management team of J B Chemicals & includes Padmini Khare Kaicker, Sumit Bose, Ranjit Shahani, Prashant Kumar, Nikhil Chopra, Gaurav Trehan, and Sandeep Phadnis, who hold various roles such as directors and compliance officer.

As of March 2023, the management team of J B Chemicals & includes the following individuals:<BR><BR>1. Padmini Khare Kaicker - Non-Executive & Independent Director<BR>2. Sumit Bose - Non-Executive & Independent Director<BR>3. Ranjit Shahani - Chairman & Independent Director<BR>4. Prashant Kumar - Non-Executive & Non-Independent Director<BR>5. Nikhil Chopra - Whole Time Director & CEO<BR>6. Gaurav Trehan - Non-Executive & Non-Independent Director<BR>7. Sandeep Phadnis - Company Secretary & Compliance Officer<BR><BR>These individuals play various roles within the company's governance and management structure.

What does J B Chemicals & do?

J B Chemicals & Pharmaceuticals Ltd manufactures and markets pharmaceutical formulations, herbal remedies, and Active Pharmaceutical Ingredients (APIs). As of March 2025, it reported net sales of ₹949 Cr and a net profit of ₹146 Cr, with a market cap of ₹26,652 Cr.

Overview: <BR>J B Chemicals & Pharmaceuticals Ltd is engaged in the manufacturing and marketing of a diverse range of pharmaceutical formulations, herbal remedies, and Active Pharmaceutical Ingredients (APIs) within the Pharmaceuticals & Biotechnology industry, categorized as a Large Cap company.<BR><BR>History: <BR>The company was originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals on December 18, 1976. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 949 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 146 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 26,652 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 40.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.90% <BR>Debt Equity: -0.12 <BR>Return on Equity: 19.21% <BR>Price to Book: 7.69 <BR><BR>Contact Details: <BR>Address: Neelam Centre 4th Floor, B-Wing Hind Cycle Road Worli Mumbai Maharashtra : 400030 <BR>Tel: 91-022-2482 2222/2493 0918 <BR>Email: investorelations@jbcpl.com <BR>Website: http://www.jbpharma.com

Has J B Chemicals & declared dividend?

J B Chemicals & Pharmaceuticals Ltd has declared an 850% dividend, amounting to ₹8.5 per share, with an ex-date of February 7, 2025. While recent short-term returns have been negative, the company has shown significant long-term growth, particularly with a total return of 404.05% over the past five years.

J B Chemicals & Pharmaceuticals Ltd has declared an 850% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 850%<BR>- Amount per share: 8.5<BR>- Ex-date: 07 Feb 2025<BR><BR>Dividend Yield: 0.9%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -2.78%, the dividend return was 0.48%, resulting in a total return of -2.3%.<BR><BR>For the 1-year period, the price return was -3.19%, the dividend return was 0.81%, leading to a total return of -2.38%.<BR><BR>Over the 2-year period, the price return was 61.46%, the dividend return was 2.56%, culminating in a total return of 64.02%.<BR><BR>In the 3-year period, the price return was 115.06%, the dividend return was 6.00%, resulting in a total return of 121.06%.<BR><BR>For the 4-year period, the price return was 126.48%, the dividend return was 7.68%, leading to a total return of 134.16%.<BR><BR>In the 5-year period, the price return was 383.78%, the dividend return was 20.27%, culminating in a total return of 404.05%.<BR><BR>Overall, J B Chemicals & Pharmaceuticals Ltd has declared a significant dividend, and while recent returns over shorter periods have been negative, the long-term performance shows substantial growth, particularly in price returns over the last five years.

Who are the peers of the J B Chemicals &?

J B Chemicals & peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Pfizer, Emcure Pharma, Wockhardt, OneSource Specialty, and ERIS Lifescience. Wockhardt has the highest 1-year return at 174.38%, while J B Chemicals & has a return of -4.32%.

Peers: The peers of J B Chemicals & are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Pfizer, Emcure Pharma, Wockhardt, OneSource Speci., and ERIS Lifescience.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, J B Chemicals &, Pfizer, Emcure Pharma, OneSource Speci., and ERIS Lifescience, while Average management risk is found at Wockhardt. Growth is excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and OneSource Speci., while Average growth is noted for J B Chemicals & and Good growth is found at Wockhardt. Below Average growth is seen at Divi's Lab., Torrent Pharma, Pfizer, and Emcure Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wockhardt at 174.38%, while the lowest is Emcure Pharma, which has no available data. J B Chemicals & has a 1-year return of -4.32%, which is lower than both the highest and the lowest. Additionally, the six-month return is negative for J B Chemicals &, Sun Pharma.Inds., Torrent Pharma, and Emcure Pharma.

Who are the top shareholders of the J B Chemicals &?

The top shareholders of J B Chemicals & include Tau Investment Holdings Pte. Ltd. with 47.84%, followed by 31 mutual fund schemes at 16.26%, 258 foreign institutional investors at 18.3%, and the Kotak Emerging Equity Scheme as the largest public shareholder at 4.25%. Individual investors collectively own 13.28% of the company.

The top shareholders of J B Chemicals & include several key players. The majority shareholder is Tau Investment Holdings Pte. Ltd., which holds 47.84% of the company. In addition, the company has a significant presence of institutional investors, with 31 mutual fund schemes holding a combined 16.26% and 258 foreign institutional investors (FIIs) owning 18.3%. The highest public shareholder is the Kotak Emerging Equity Scheme, which holds 4.25%. Individual investors collectively own 13.28% of the company.

How big is J B Chemicals &?

As of 24th July, J B Chemicals & Pharmaceuticals Ltd has a market capitalization of 26,460.00 Cr, with recent Net Sales of 3,917.99 Cr and a Net Profit of 659.58 Cr. Shareholder's Funds are valued at 3,433.32 Cr, and Total Assets amount to 4,265.36 Cr.

As of 24th July, J B Chemicals & Pharmaceuticals Ltd has a market capitalization of 26,460.00 Cr, classifying it as a Large Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 3,917.99 Cr and a Net Profit of 659.58 Cr.<BR><BR>For the latest annual period, the Shareholder's Funds were valued at 3,433.32 Cr, while the Total Assets amounted to 4,265.36 Cr.

Is J B Chemicals & technically bullish or bearish?

As of November 7, 2025, J B Chemicals & shows a mildly bullish trend driven by daily moving averages, despite caution from weekly and monthly indicators like MACD and KST, while volatility remains low according to Bollinger Bands.

As of 7 November 2025, the technical trend for J B Chemicals & has changed from sideways to mildly bullish. The daily moving averages indicate a bullish stance, while the weekly and monthly MACD and KST readings are mildly bearish, suggesting some caution. The RSI shows no signals in both weekly and monthly time frames, and Bollinger Bands are sideways, indicating a lack of volatility. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages, despite the bearish signals from other indicators.

Are J B Chemicals & latest results good or bad?

J B Chemicals reported a mixed performance in Q2 FY26, with a net profit increase of 19.05% to ₹207.82 crore and revenue growth of 8.42% to ₹1,084.90 crore. However, there was a slight sequential revenue decline of 0.83%, raising concerns about future growth despite strong profitability metrics.

J B Chemicals has reported a mixed performance in its latest results for Q2 FY26. On the positive side, the company achieved a net profit of ₹207.82 crore, which represents a significant year-on-year increase of 19.05%. Additionally, revenue rose to ₹1,084.90 crore, marking an 8.42% increase compared to the same quarter last year. The operating margin also improved to 28.54%, reflecting a strong operational performance with a 150 basis point increase year-on-year.<BR><BR>However, there are some concerns as well. The revenue showed a slight sequential decline of 0.83% compared to the previous quarter, indicating potential near-term challenges in demand. While the net profit increased by 2.69% quarter-on-quarter, the revenue growth appears to be slowing down, which could raise questions about future performance.<BR><BR>Overall, while the profitability metrics are strong and the company is demonstrating effective cost management and capital efficiency, the sequential decline in revenue may signal some caution for investors. The company's ability to maintain its growth trajectory will be crucial moving forward.

How has been the historical performance of J B Chemicals &?

J B Chemicals & has shown consistent growth in net sales and profitability, with net sales increasing from 1,643.20 Cr in Mar'19 to 3,917.99 Cr in Mar'25, and profit after tax rising from 193.97 Cr to 659.58 Cr during the same period. The company also improved its operational efficiency and maintained a solid balance sheet, with total assets growing significantly.

Answer:<BR>The historical performance of J B Chemicals & shows a consistent growth trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>J B Chemicals & has demonstrated significant growth in net sales, increasing from 1,643.20 Cr in Mar'19 to 3,917.99 Cr in Mar'25. This upward trajectory reflects a robust annual growth rate, particularly notable from Mar'24 to Mar'25, where sales rose from 3,484.18 Cr to 3,917.99 Cr. The total operating income followed a similar pattern, reaching 3,917.99 Cr in Mar'25. Operating profit, excluding other income, also improved significantly, rising from 305.39 Cr in Mar'19 to 1,031.84 Cr in Mar'25, indicating enhanced operational efficiency. Profit before tax increased from 286.99 Cr in Mar'19 to 887.39 Cr in Mar'25, while profit after tax surged from 193.97 Cr to 659.58 Cr in the same period. The company's total assets grew from 1,813.98 Cr in Mar'20 to 4,265.36 Cr in Mar'25, reflecting a solid asset base. Total liabilities increased from 1,813.98 Cr to 4,265.36 Cr, with a notable reduction in long-term borrowings to zero by Mar'25. Cash flow from operating activities improved significantly, reaching 902.00 Cr in Mar'25, contributing to a closing cash balance of 115.00 Cr. Overall, J B Chemicals & has shown a strong upward trend in both revenue and profitability, alongside a solid balance sheet position.

Should I buy, sell or hold J B Chemicals &?

Which are the latest news on J B Chemicals &?

Why is J B Chemicals & falling/rising?

As of 03-Dec, J B Chemicals & Pharmaceuticals Ltd's stock price is rising slightly at 1,766.00, following a trend reversal after declines. Despite a year-to-date decline, the stock shows positive long-term growth and strong financial metrics, although there are concerns about decreased investor participation.

As of 03-Dec, J B Chemicals & Pharmaceuticals Ltd's stock price is experiencing a slight rise, currently at 1,766.00, reflecting an increase of 1.8 (0.1%). This upward movement follows a trend reversal after two consecutive days of decline. The stock's performance today is reported to be in line with the sector, indicating a stable position amidst market fluctuations.<BR><BR>Despite a year-to-date decline of 4.22% compared to the Sensex's gain of 8.92%, the stock has shown positive momentum over the past month, with a 3.03% increase. Additionally, the stock has demonstrated impressive long-term growth, with a 76.61% increase over three years and a remarkable 255.74% rise over five years. <BR><BR>However, there are some concerns affecting investor sentiment. The delivery volume has decreased by 24.08% against the five-day average, indicating falling investor participation. Furthermore, while the stock is trading above its 50-day, 100-day, and 200-day moving averages, it is below its 5-day and 20-day moving averages, suggesting mixed short-term trends.<BR><BR>On a positive note, the company maintains high management efficiency, evidenced by a return on equity (ROE) of 19.25% and a low debt-to-equity ratio of 0.02 times. The recent positive financial results, including the highest operating cash flow and profit before depreciation, interest, and taxes, further bolster confidence. Additionally, high institutional holdings at 38.13%, which have increased by 0.73% over the previous quarter, indicate strong backing from knowledgeable investors.<BR><BR>In summary, the stock's current rise can be attributed to a trend reversal after previous declines, solid long-term performance, and positive financial metrics, despite some short-term challenges regarding investor participation.